Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:8567
Name Hodgkin's lymphoma
Definition A lymphoma that is marked by the presence of a type of cell called the Reed-Sternberg cell.
Source DiseaseOntology.org
Alt Ids DOID:8953 DOID:0060059 DOID:8710 DOID:8652 DOID:8685 DOID:8671 DOID:9107 DOID:8715 DOID:8841 DOID:9096
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma Hodgkin's lymphoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
CSF1R positive Sorafenib Hodgkin's lymphoma sensitive detail...
CSF1R positive N/A Hodgkin's lymphoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00513474 Phase I Rasburicase Methotrexate Sirolimus Cyclosporine Tacrolimus Filgrastim Busulfan + Cyclophosphamide + Etoposide Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant Completed USA 0
NCT00576654 Phase I Irinotecan Veliparib Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT00602693 Phase I Sirolimus Allopurinol + Cyclophosphamide + Fludarabine T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer Completed USA 0
NCT00838955 Phase II Temsirolimus Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma Terminated USA 0
NCT00857389 Phase II Cyclophosphamide Filgrastim Tacrolimus Thiotepa anti-thymocyte globulin + Busulfan + Clofarabine Methotrexate Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies Completed USA 0
NCT01028716 Phase II Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Terminated USA 0
NCT01032148 Phase I Panobinostat Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma Terminated USA 0
NCT01076543 Phase Ib/II Lenalidomide + Temsirolimus Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma Completed USA 0
NCT01169636 Phase Ib/II Panobinostat Pegfilgrastim Carboplatin + Etoposide + Ifosfamide Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma Completed USA 0
NCT01196208 Expanded access Brentuximab vedotin A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 No longer available USA | ITA | FRA | ESP | DEU | BEL 9
NCT01251575 Phase II Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Completed USA 1
NCT01333046 Phase I MultiTAA-specific T cells Azacitidine + MultiTAA-specific T cells Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL (TACTAL) Active, not recruiting USA 0
NCT01476839 Phase I Basiliximab + Carmustine + Cytarabine + Etoposide + Melphalan + Yttrium Y 90 Basiliximab Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma Active, not recruiting USA 0
NCT01592370 Phase I Nivolumab Ipilimumab Lirilumab Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma Active, not recruiting USA | ITA | FRA | BEL 2
NCT01609816 Phase Ib/II Dasatinib Dasatinib in Treating Patients With Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated With Autologous Stem Cell Transplant Terminated USA 0
NCT01621477 Phase II Plerixafor Tacrolimus Mycophenolate mofetil anti-thymocyte globulin + Busulfan + Clofarabine Cyclophosphamide + Cytarabine T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant Terminated USA 0
NCT01701986 Phase Ib/II Tacrolimus Rituximab Filgrastim Mycophenolate mofetil anti-thymocyte globulin Busulfan + Clofarabine + Gemcitabine Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas Active, not recruiting USA 0
NCT01716806 Phase II Brentuximab vedotin + Nivolumab Bendamustine + Brentuximab vedotin Brentuximab vedotin + Dacarbazine Brentuximab vedotin A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL) Recruiting USA | CAN 0
NCT01742988 Phase Ib/II Bendamustine + CUDC-907 + Rituximab CUDC-907 + Rituximab CUDC-907 CUDC-907 + Venetoclax Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma Completed USA 0
NCT01745354 Phase I SD-101 Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT) Terminated USA 0
NCT01811368 Phase II anti-thymocyte globulin + Ibritumomab tiuxetan + Rituximab Cyclosporine + Mycophenolate mofetil Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT01822509 Phase I Ipilimumab + Nivolumab Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant Completed USA 0
NCT01896999 Phase I Brentuximab vedotin + Ipilimumab Ipilimumab and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Recruiting USA 0
NCT01897012 Phase I Romidepsin Alisertib Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas Completed USA 0
NCT01905813 Phase I Dezapelisib + Itacitinib Dezapelisib Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies Active, not recruiting USA 0
NCT01949883 Phase I CPI-0610 A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma Completed 0
NCT01953692 Phase I Pembrolizumab A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013) Completed 0
NCT01983969 Phase Ib/II Rituximab Dexamethasone Busulfan + Melphalan Azacitidine + Gemcitabine + Vorinostat Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma Completed USA 0
NCT02018861 Phase I Itacitinib Itacitinib + Parsaclisib Bendamustine Rituximab Carboplatin + Etoposide + Ifosfamide Parsaclisib A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies Completed USA 0
NCT02061761 Phase Ib/II Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies Completed USA | CAN 0
NCT02091063 Phase Ib/II Ricolinostat ACY-1215 for Relapsed/Refractory Lymphoid Malignancies Completed USA 0
NCT02098512 Phase Ib/II Brentuximab vedotin Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients Unknown status USA 0
NCT02104427 Phase II Burixafor Filgrastim PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients Completed USA 0
NCT02130869 Phase I Bendamustine + Cytarabine + Etoposide Busulfan + Hu14.18K322A Aldesleukin + Melphalan + Sargramostim Filgrastim Carboplatin + Etoposide A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas Completed USA 0
NCT02164006 Phase I Umbralisib Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients Completed USA 0
NCT02181218 Phase I Pegfilgrastim Romidepsin Dexamethasone + Gemcitabine + Oxaliplatin Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas Completed USA 0
NCT02181738 Phase II Nivolumab Study of Nivolumab in Subjects With Hodgkin's Lymphoma (Registrational) (CheckMate 205) Active, not recruiting USA | ITA | ESP | DEU | CAN | BEL | AUT 3
NCT02200380 Phase II Plerixafor CDX-301 A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs Terminated USA 0
NCT02203903 Phase I MultiTAA-specific T cells Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE) Recruiting USA 0
NCT02208037 Phase II Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Completed USA 0
NCT02227199 Phase Ib/II Brentuximab vedotin + Carboplatin + Etoposide + Ifosfamide Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE) Active, not recruiting USA 0
NCT02254239 Phase I Everolimus Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Terminated USA 0
NCT02287311 Phase I LMP/BARF1/EBNA1-specific cytotoxic T lymphocytes Cyclophosphamide + Fludarabine Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) Recruiting USA 0
NCT02304458 Phase Ib/II Ipilimumab + Nivolumab Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Active, not recruiting USA | CAN 0
NCT02327078 Phase Ib/II Epacadostat + Nivolumab A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers Completed USA 1
NCT02332668 Phase Ib/II Pembrolizumab A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) Recruiting USA | ITA | FRA | DEU 6
NCT02343666 Phase I Filgrastim Carmustine Plerixafor O6-benzylguanine HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection Withdrawn USA 0
NCT02362997 Phase II Pembrolizumab Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL Active, not recruiting USA 0
NCT02376699 Phase I Pembrolizumab + SEA-CD40 SEA-CD40 Safety Study of SEA-CD40 in Cancer Patients Active, not recruiting USA 0
NCT02398240 Phase II Brentuximab vedotin + Doxorubicin + Rituximab + Vincristine Sulfate Brentuximab vedotin + Doxorubicin + Vincristine Sulfate Brentuximab for Newly Diagnosed Hodgkin Disease Active, not recruiting USA 0
NCT02408042 Phase Ib/II Rituximab Carboplatin + Etoposide + Ifosfamide Pembrolizumab Brentuximab vedotin Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) Withdrawn USA 0
NCT02429375 Phase Ib/II Brentuximab vedotin + Mocetinostat Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma Completed USA 0
NCT02453594 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087) Active, not recruiting 0
NCT02541604 Phase I Atezolizumab A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors Terminated USA | ITA | FRA | ESP | DEU | CAN 5
NCT02572167 Phase Ib/II Brentuximab vedotin + Nivolumab A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma Completed USA 0
NCT02576496 Phase I Tinostamustine Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies Recruiting USA | ITA | FRA | ESP | DEU 2
NCT02595866 Phase I Pembrolizumab Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms Recruiting USA 0
NCT02603419 Phase I Avelumab Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS) Terminated USA | ITA 1
NCT02613598 Phase I Bortezomib + Ruxolitinib Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma Completed USA 0
NCT02624258 Phase I RNA CART19 cells Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma Terminated USA 0
NCT02651662 Phase I Cemiplimab Cemiplimab + Odronextamab Study of REGN2810 and REGN1979 in Patients With Lymphoma Active, not recruiting USA | ESP | DEU 0
NCT02661503 Phase III Brentuximab vedotin + Cyclophosphamide + Dacarbazine + Dexamethasone + Doxorubicin + Etoposide Bleomycin + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Procarbazine + Vincristine Sulfate HD21 for Advanced Stages Recruiting DEU 0
NCT02663297 Phase I ATLCAR.CD30 cells Administration of T Lymphocytes for Prevention of Relapse of Lymphomas Active, not recruiting USA 0
NCT02665650 Phase I AFM13 + Pembrolizumab Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Completed USA | ESP 0
NCT02684292 Phase III Brentuximab vedotin Pembrolizumab Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) Active, not recruiting 0
NCT02690545 Phase Ib/II ATLCAR.CD30 cells Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL Recruiting USA 0
NCT02701673 Phase Ib/II Azacitidine Pyridoxine Gemcitabine Belinostat Busulfan Melphalan Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma Withdrawn 0
NCT02722668 Phase II Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Recruiting USA 0
NCT02727803 Phase II anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma Recruiting USA 0
NCT02744612 Phase II Brentuximab vedotin + Ibrutinib Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Active, not recruiting USA 0
NCT02758717 Phase II Brentuximab vedotin + Nivolumab Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma Active, not recruiting USA 0
NCT02763254 Phase II CMD-003 Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas (CIVIC) Terminated USA 0
NCT02797470 Phase Ib/II Carmustine + CCR5 shRNA/TRIM5a/TAR decoy-transduced CD34+ HPCs + Cytarabine + Etoposide + Melphalan Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant Recruiting USA 0
NCT02824029 Phase II Ibrutinib Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Active, not recruiting USA 0
NCT02867618 Phase Ib/II Carfilzomib + Umbralisib Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma Terminated USA 0
NCT02869633 Phase II Ibrutinib Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant Active, not recruiting USA 0
NCT02875067 Phase Ib/II Lenalidomide + Pembrolizumab Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma Terminated USA 0
NCT02890758 Phase I ALT-803 Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Active, not recruiting USA 0
NCT02917083 Phase I ATLCAR.CD30 cells + Cyclophosphamide + Fludarabine CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) Recruiting USA 0
NCT02927769 Phase II Brentuximab vedotin + Nivolumab Bendamustine + Brentuximab vedotin A Study of Nivolumab + Brentuximab Vedotin in Children, Adolescents, and Young Adults With Classic Hodgkin Lymphoma (cHL) After Failure of First Line Therapy, Followed by Brentuximab Vedotin + Bendamustine for Participants With a Suboptimal Response (CheckMate 744) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN 5
NCT02931110 Phase I CBL0137 Study of IV CBL0137 in Previously Treated Hematological Subjects Terminated USA 0
NCT02940301 Phase II Ibrutinib + Nivolumab Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Active, not recruiting USA 0
NCT02960646 Phase I Fludarabine + Melphalan CD45RA-depleted donor lymphocytes Cyclophosphamide Tacrolimus Rituximab Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting USA 0
NCT02961816 Phase II Pyridoxine Busulfan + Gemcitabine + Melphalan + Panobinostat Dexamethasone + Filgrastim + Palifermin + Rituximab Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma Withdrawn 0
NCT02973113 Phase I EB-VST cells + Nivolumab Nivolumab With Epstein Barr Virus Specific T Cells (EB-VSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (PREVALE) Completed USA 0
NCT03013933 Phase I Brentuximab vedotin + Cyclosporine + Verapamil Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Active, not recruiting USA 0
NCT03015896 Phase Ib/II Lenalidomide + Nivolumab Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Recruiting USA 0
NCT03016871 Phase II Nivolumab Carboplatin + Etoposide + Ifosfamide + Nivolumab Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL Recruiting USA 0
NCT03033914 Phase I Dacarbazine + Doxorubicin + Nivolumab + Vinblastine Bleomycin + Dacarbazine + Doxorubicin + Nivolumab + Vinblastine A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma Recruiting USA | CAN 0
NCT03049449 Phase I ATLCAR.CD30 cells Cyclophosphamide + Fludarabine T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Completed USA 0
NCT03057795 Phase II Brentuximab vedotin + Nivolumab Nivolumab and Brentuximab Vedotin After Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Classical Hodgkin Lymphoma Active, not recruiting USA 0
NCT03077828 Phase II Carboplatin + Etoposide + Ifosfamide + Pembrolizumab Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Active, not recruiting USA 0
NCT03120676 Phase II Atezolizumab Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma Terminated USA 0
NCT03138499 Phase III Brentuximab vedotin Brentuximab vedotin + Nivolumab Phase III Trial of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant, Terminated USA 2
NCT03150329 Phase I Pembrolizumab + Vorinostat Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma Active, not recruiting USA 0
NCT03179917 Phase II Pembrolizumab Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma Recruiting USA 0
NCT03179930 Phase II Entinostat + Pembrolizumab Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas Recruiting USA 0
NCT03212404 Phase I Cosibelimab Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Recruiting FRA | ESP 7
NCT03226249 Phase II Dacarbazine + Doxorubicin + Pembrolizumab + Vinblastine PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma Unknown status USA 0
NCT03233347 Phase II Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Vinblastine Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma Active, not recruiting USA 0
NCT03236935 Phase I L-NMMA + Pembrolizumab Phase Ib of L-NMMA and Pembrolizumab Active, not recruiting USA 0
NCT03259503 Phase Ib/II Busulfan Olaparib Vorinostat Palifermin Gemcitabine Melphalan Dexamethasone Pyridoxine Rituximab Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas Recruiting USA 0
NCT03331341 Phase II Dacarbazine + Doxorubicin + Pembrolizumab + Vinblastine Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma Recruiting USA 0
NCT03331731 Phase II Pembrolizumab A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma (PLIMATH) Recruiting 2
NCT03337919 Phase II Nivolumab ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma (ANIMATE) Recruiting 1
NCT03357757 Phase II Avelumab + Valproic acid Avelumab With Valproic Acid in Virus-associated Cancer (LATENT) Recruiting CAN 0
NCT03407144 Phase II Cyclophosphamide + Doxorubicin + Etoposide + Pembrolizumab + Prednisone + Vincristine Sulfate Bleomycin + Dacarbazine + Doxorubicin + Pembrolizumab + Vinblastine Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) Recruiting USA | ITA | FRA | ESP | DEU 10
NCT03432741 Phase I Carfilzomib Daratumumab Obinutuzumab Gemcitabine Trastuzumab Romidepsin Nivolumab Rituximab Belinostat Pembrolizumab Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Recruiting USA 0
NCT03436862 Phase II Nivolumab Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression Active, not recruiting USA 0
NCT03471351 Phase Ib/II Pembrolizumab + Tenalisib Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL Terminated USA 0
NCT03480360 Phase III Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Recruiting USA 0
NCT03495713 Phase II Nivolumab RADVAX FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS Terminated USA 0
NCT03517137 Phase II Brentuximab vedotin + Dacarbazine + Doxorubicin + Vinblastine Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Nivolumab + Prednisone + Rituximab Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study (COBRA) Active, not recruiting ESP | BEL 5
NCT03580408 Phase II Nivolumab + Vinblastine Nivolumab Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma Active, not recruiting FRA | BEL 0
NCT03598608 Phase Ib/II MK-4280 + Pembrolizumab Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) Recruiting USA | ITA | DEU | CAN 2
NCT03602157 Phase I ATLCAR.CD30.CCR4 cells Bendamustine + Fludarabine ATLCAR.CD30 cells + ATLCAR.CD30.CCR4 cells Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL Recruiting USA 0
NCT03617666 Phase II Avelumab Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study (AVENuE) Active, not recruiting 2
NCT03618550 Phase II Doxorubicin + Gemcitabine + Pembrolizumab + Vinorelbine Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma Recruiting USA 0
NCT03646123 Phase II Brentuximab vedotin + Dacarbazine + Doxorubicin + Filgrastim + Vinblastine Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Active, not recruiting USA | ITA | ESP 3
NCT03652441 Phase II Brentuximab vedotin Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma Recruiting DEU 0
NCT03674411 Phase II Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy Active, not recruiting USA 0
NCT03681561 Phase Ib/II Nivolumab + Ruxolitinib Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma Recruiting USA 0
NCT03697408 Phase Ib/II Everolimus + Itacitinib Itacitinib + Everolimus in Hodgkin Lymphoma Recruiting USA 0
NCT03712202 Phase II Nivolumab Brentuximab vedotin + Nivolumab Brentuximab vedotin + Dacarbazine + Doxorubicin + Vinblastine Bleomycin + Dacarbazine + Doxorubicin + Vinblastine Brentuximab Vedotin and Nivolumab in Treating Participants With Early Stage Classic Hodgkin Lymphoma Recruiting USA 0
NCT03739606 Phase II Flotetuzumab Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Withdrawn 0
NCT03739619 Phase Ib/II Bendamustine + Gemcitabine + Nivolumab Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Active, not recruiting USA 0
NCT03755804 Phase II Bendamustine + Bleomycin + Doxorubicin + Etoposide + Prednisone + Vinblastine + Vincristine Sulfate Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 Recruiting USA 0
NCT03776864 Phase II Pembrolizumab + Umbralisib Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Terminated USA 0
NCT03778073 Phase I Cosibelimab Study of TG-1501 in Subjects With Relapsed or Refractory Lymphoma Active, not recruiting USA 0
NCT03809624 Phase I INBRX-105 Study of INBRX-105 in Patients With Solid Tumors (PDL1x41BB) Recruiting USA 0
NCT03816345 Phase I Nivolumab Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Recruiting USA | CAN 0
NCT03843294 Phase I MultiTAA-specific T cells + Nivolumab Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma Recruiting USA 0
NCT03885947 Phase I Cyclophosphamide + Fludarabine + Thiotepa VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies Completed USA 0
NCT03894618 Phase I SL-279252 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Recruiting USA | ESP | CAN | BEL 0
NCT03907488 Phase III Pegfilgrastim Brentuximab vedotin + Dacarbazine + Doxorubicin + Vinblastine Filgrastim Dacarbazine + Doxorubicin + Nivolumab + Vinblastine Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma Recruiting USA | CAN 1
NCT03920631 Phase I Nivolumab Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ) Withdrawn USA 0
NCT03921879 Phase I OT-82 Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma Recruiting USA 0
NCT03925935 Phase I AB-205 Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation Completed USA 0
NCT03947255 Phase II Brentuximab vedotin A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma Recruiting USA 0
NCT03983668 Phase Ib/II Pembrolizumab + Vidutolimod CMP-001 for Relapsed and Refractory Lymphoma Recruiting USA 0
NCT04016116 Phase II Pembrolizumab + Ruxolitinib Pembrolizumab Dual PD-1 and JAK2 Inhibition in Hematological Malignancies Withdrawn USA 0
NCT04052997 Phase II Camidanlumab Tesirine Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL 4
NCT04074746 Phase I Cyclophosphamide + Fludarabine AFM13 Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas Recruiting USA 0
NCT04134325 Phase I Nivolumab Pembrolizumab Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma Recruiting USA 0
NCT04160195 Phase I Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma Terminated USA 0
NCT04233697 Phase I Copanlisib + Romidepsin Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma Withdrawn 0
NCT04254107 Phase I SGN-TGT Pembrolizumab + SGN-TGT A Safety Study of SGN-TGT in Patients With Advanced Cancer Recruiting USA | ITA | FRA | ESP | CAN 1
NCT04318080 Phase II Tislelizumab Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma Recruiting USA | FRA | BEL 2
NCT04464798 Phase I Iberdomide Iberdomide + Obinutuzumab Iberdomide + Rituximab A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas Recruiting USA | ITA | FRA | DEU 2
NCT04491370 Phase Ib/II Polatuzumab vedotin-piiq Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma Recruiting USA 0
NCT04510636 Phase II Bendamustine + Pembrolizumab Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma Recruiting CAN 0
NCT04561206 Phase II Brentuximab vedotin + Nivolumab Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed Classical Hodgkin Lymphoma Recruiting USA 0
NCT04681105 Phase I Acetaminophen + Dexamethasone + Diphenhydramine + Flotetuzumab + Ranitidine Dexamethasone + Diphenhydramine + Flotetuzumab + Ibuprofen + Ranitidine Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies Recruiting USA 0
NCT04684108 Phase I SG301 SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies Not yet recruiting 1
NCT04685616 Phase III Brentuximab vedotin + Dacarbazine + Doxorubicin + Filgrastim + Vinblastine Bleomycin + Dacarbazine + Doxorubicin + Vinblastine Brentuximab Vedotin in Early Stage Hodgkin Lymphoma (RADAR) Recruiting 1
NCT04788043 Phase II Hu5F9-G4 + Pembrolizumab Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma Recruiting USA 0
NCT04837859 Phase II Tislelizumab Dacarbazine + Doxorubicin + Tislelizumab + Vinblastine Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma (INDIE) Not yet recruiting DEU 0
NCT04838652 Phase II Cisplatin + Cytarabine + Dexamethasone + Pembrolizumab Carboplatin + Etoposide + Ifosfamide + Pembrolizumab Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma (Pembro-CORE) Not yet recruiting DEU 0
NCT04842877 Phase II DS-3201b Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma Recruiting FRA | BEL 0
NCT04866654 Phase II Nivolumab Radiation Free Chemotherapy for Early Hodgkin Lymphoma (RAFTING) Recruiting ITA | ESP 1
NCT04871607 Phase II Basiliximab + Carmustine + Cytarabine + Etoposide + Filgrastim + Yttrium Y 90 Basiliximab Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma Recruiting USA 0
NCT04875195 Phase II Pembrolizumab A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) Recruiting USA | ITA | FRA | CAN 7
NCT04902443 Phase I Nivolumab + Pomalidomide Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV Recruiting USA 0
NCT04920383 Phase I ALPN-202 + unspecified PD-1 antibody ALPN-202 With PD-1 Inhibition in Advanced Malignancies (NEON-2) Recruiting USA 0
NCT04938232 Phase II Ipilimumab + Nivolumab Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL Recruiting USA 0
NCT05005442 Phase II MK-7684A A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004) Recruiting USA | ITA | FRA | ESP | DEU | CAN 10
NCT05008224 Phase II Bleomycin + Cyclophosphamide + Doxorubicin + Etoposide + Pembrolizumab + Prednisone + Procarbazine + Vincristine Sulfate Dacarbazine + Doxorubicin + Pembrolizumab + Vinblastine Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11) (KEYNOTE-C11) Active, not recruiting USA | ITA | FRA | ESP | CAN 6
NCT05011058 Phase II CHR-3996 CHR-3996 + Valganciclovir An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1) Recruiting USA | ITA | FRA | DEU | CAN 4
NCT05039073 Phase II Brentuximab vedotin + Nivolumab Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors Recruiting USA 0
NCT05134740 Phase I MultiTAA-specific T cells (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL). Recruiting USA 0
NCT05140382 Phase II AZD4573 AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL Recruiting USA | ITA | FRA 6
NCT05162976 Phase I Azacitidine + Nivolumab CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed Recruiting USA 0
NCT05179603 Phase II THOR-707 Pembrolizumab + THOR-707 A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) Recruiting ESP 2
NCT05181540 Phase III AB-205 A Phase 3 Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation (E-CELERATE) Recruiting USA 0
NCT05216835 Phase Ib/II AZD7789 Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Recruiting USA | ITA | FRA | ESP | DEU | CAN 2
NCT05253495 Phase II Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Rituximab + Vincristine Sulfate Cyclophosphamide + Dexamethasone + Vincristine Sulfate Cytarabine + Etoposide + Polatuzumab vedotin-piiq + Rituximab Cytarabine + Etoposide + Polatuzumab vedotin-piiq Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Polatuzumab vedotin-piiq Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Polatuzumab vedotin-piiq + Rituximab Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Rituximab + Vinblastine Brentuximab vedotin + Nivolumab + Rituximab + Vinblastine Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Vinblastine Cytarabine + Methotrexate + Rituximab Brentuximab vedotin + Dacarbazine + Doxorubicin + Rituximab + Vinblastine Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma (RADICAL) Recruiting USA 0
NCT05255601 Phase Ib/II Nivolumab + Relatlimab A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069) Not yet recruiting USA | ITA | FRA | ESP | DEU 3
NCT05272384 Phase I Decitabine and Cedazuridine + Nivolumab Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma Recruiting USA 0
NCT05279300 Phase I CS5001 A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas Recruiting USA 1
NCT05293912 Phase I SG2501 SG2501 Safety Study in Subjects With Relapsed or Refractory Hematological Malignancies and Lymphoma. Recruiting USA 0
NCT05300282 Phase Ib/II Atezolizumab + Bendamustine + Gemcitabine + Vinorelbine Bendamustine + Gemcitabine + Vinorelbine Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients (FIL_A-BEGEV) Not yet recruiting ITA 0
NCT05337735 Phase II XmAb20717 A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers Recruiting USA 0
NCT05346809 Phase II Isatuximab Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma Recruiting USA 0
NCT05352828 Phase I Bendamustine + Fludarabine ATLCAR.CD30 cells + Nivolumab Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy (ACTION) Recruiting USA 0
NCT05355051 Phase II Azacitidine + Pembrolizumab A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma Not yet recruiting USA 0
NCT05400122 Phase I Aldesleukin + TEW 7197 Cyclophosphamide + Fludarabine Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Not yet recruiting USA 0
NCT05404945 Phase II Dacarbazine + Doxorubicin + Pembrolizumab + Vinblastine Brentuximab vedotin + Pembrolizumab Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above Recruiting USA 0